Dr. Dopheide is a board certified psychiatric pharmacist who provides clinical service for adults and children with psychiatric illness at Los Angeles County + USC Medical Center. Her research has included assessing the tolerability of valproate loading doses, and expanding direct patient care roles for psychiatric pharmacists. She is USC’s PGY2 Psychiatric Pharmacy residency program director and supervises pharmacy residents and students in the provision of comprehensive medication management on the inpatient psychiatry service and in clinics. She is actively involved in teaching pharmacy students, medical students, allied health, and psychiatry residents in both the classroom and clinical settings.
Professor Dopheide's excellence as an educator is recognized nationally and internationally. She has over 40 publications in peer-reviewed journals, textbooks, and educational resources. She has been a visiting professor at Tokyo University of Pharmacy and Life Sciences and twice served as a Healthcare Manpower Development Expert for the Ministry of Health in Singapore. She serves as an invited speaker for several national pharmacy organizations including the American Pharmacists Association (APhA), the American Society of Health System Pharmacists (ASHP), and the College of Psychiatric and Neurologic Pharmacists (CPNP). She is currently vice-chair of the Board of Pharmacy Specialties Psychiatric Specialty Council and served as President of CPNP in 2013-2014.
Areas of Expertise (6)
Insomnia and Sleep Disorders
Depression and Bipolar Disorder
Attention Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (Asd)
Comprehensive Medication Managment
Recipient of the College of Psychiatric and Neurologic Pharmacists
Judith J. Saklad Memorial award for achieving a level of professional distinction as a senior psychiatric pharmacist
Advanced Practice Pharmacy Experience Preceptor of the Year
2017 - 2018
2001 - 2002
Professor of the Year
President of the College of Psychiatric and Neurologic Pharmacists
2013 - 2014
University of Southern California: Residency, Psychiatric Pharmacy 1989
University of Nebraska: Pharm.D., Pharmaceutical Sciences 1988
- Vice-chair Board of Pharmacy Specialties (BPS) Psychiatric Specialty Council: 2019-2021
- American Society of Hospital Pharmacists : Member
- American Pharmacists Association : Member
- American Association of Colleges of Pharmacy : Member
- NAMI : Member
- College of Psychiatric and Neurologic Pharmacists: Member
- College of Psychiatric and Neurologic Pharmacists Foundation: Founding Member
Selected Media Appearances (2)
Empathy, tech combine to improve autism awareness and research
“Thanks to improved public health education on autism spectrum disorder, most parents and providers now recognize that vaccines do not cause ASD. Potential causes are many and include genetics and toxins in the environment"...
Counseling Points for Treating Patients with Depression, Anxiety and Insomnia
Julie Dopheide, PharmD, BCPP, FASHP, outlines several counseling points for treating patients with depression, anxiety and insomnia...
Research Focus (1)
Tolerability of Psychotropics
Dr. Dopheide's research includes investigating the tolerability of psychotropics and expanding roles for board certified psychiatric pharmacists to improve patient's health outcomes
Research Grants (2)
PGY2 Resident Research
Board of Pharmacy Specialties $5,000
Support an additional PGY2 resident
Selected Articles (8)
Fay Goldenshteyn, Julie Ann Dopheide, Mimi Lou
The pharmacy profession has promoted the value of board certification, yet the impact of board certification on employment opportunities for pharmacists is largely unknown. This study aims to report employer preferences for board certification as indicated on job listings.
Julie Ann Dopheide
The American Society of Health-System Pharmacists' Postgraduate Year 1 and Year 2 Residency Accreditation Standards require that residents demonstrate effective teaching skills. The College of Psychiatric and Neurologic Pharmacists' survey of pharmacy program curricula assessed resident teaching in psychiatry and neurology, however, results were not published. The objective of this article is to describe resident teaching in psychiatry and neurology curricula as reported by responses to the college's survey.
Julie Ann Dopheide; Lisa W Goldstone
To describe pharmacy curricula in psychiatry and neurology and to report on neuropsychiatric pharmacy specialists' views on optimal curriculum. Design and administer one electronic survey to accredited pharmacy programs asking them to report information on curricula in psychiatry and neurology for the 2014-2015 academic year. Design and administer a separate electronic survey to board certified pharmacists with an academic affiliation who are members of the College of Psychiatric and Neurologic Pharmacists (CPNP) asking about their teaching activities and their opinion on optimal curricula. Fifty-six percent of pharmacy programs and 65% of CPNP members responded to the surveys. The program survey revealed greater than 80% of topics were taught by full-time faculty. Didactic lecturing, team-based learning, and case studies were the most common teaching methods. Programs dedicated the most didactics (3 to 5+ hours) to epilepsy, depression, schizophrenia, substance use disorders, and pain. Autism, traumatic brain injury, personality, and eating disorders were either not taught or given ≤ 1 hour of didactics in most programs. Inpatient psychiatry had the most APPE placements with a mean of 19.6, range 0-83. APPE electives in psychiatry outnumbered those in neurology 5 to 1. CPNP member survey results showed 2 out of 3 members agreed that curriculum could be improved with additional APPEs in psychiatry and neurology. Didactic hour distribution in psychiatry and neurology could be improved to better align with board certification in psychiatric pharmacy (BCPP) recommendations and disorder prevalence and complexity. Specialists recommend an experiential component in neurology and psychiatry to combat stigma and improve pharmacist knowledge and skills.
Julie Ann Dopheide
Early recognition and treatment of agitated patients is essential to avoid violence in the psychiatric emergency department (ED). Antipsychotics have established efficacy in managing agitation, yet little is known about how the choice of initial antipsychotic impacts time to repeat use and length of stay (LOS) in the psychiatric ED.
A 17-year-old Hispanic male with ASD and intellectual disability was hospitalized for inpatient psychiatric treatment due to impulsive and violent behavior. Despite receiving various medications in the initial weeks of hospitalization, including intramuscular lorazepam and diphenhydramine injections (four days a week on average), the patient continued to exhibit aggressive and unpredictable behaviors.
Williams AM, Dopheide JA
Studies have demonstrated the benefits of incorporating comprehensive medication management into primary care, but no study describes the types of nonpsychiatric medication-related interventions provided by a psychiatric pharmacist while providing comprehensive medication management.
Nazarian PK, Dopheide JA
To evaluate the usefulness of a depression screening tool in a university campus pharmacy.